Jefferies is resuming coverage on shares of Myriad Genetics (NASDAQ: MYGN) with a Buy rating and $26 price target.

This article: 240 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE